MYR Pharmaceuticals is focused on the development of Bulevirtide (formally known as Myrcludex B), a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. We started our operations in 2011. Our technology was originally developed at the University of Heidelberg (Germany) and INSERM (France) and represents one the most clinically advanced novel approaches for treatment of hepatitis B and D.

Around 15-20 million people develop chronic hepatitis D virus worldwide. A vaccine against hepatitis B is today the only method to prevent HDV infection. At MYR Group we fully dedicate our work to bring benefit to Hepatitis D patients targeting a disease with high unmet medical need.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for HEPCLUDEX® (Bulevirtide, formerly known as Myrcludex B), the First-in-Class Entry Inhibitor for the treatment of chronic hepatitis D infections.